Page last updated: 2024-11-05

skatole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Skatole, also known as 3-methylindole, is a naturally occurring organic compound found in feces and other biological sources. It is produced by the breakdown of tryptophan by bacteria in the gut. Skatole has a strong fecal odor, and it is a key contributor to the characteristic smell of feces. It is also found in some foods, such as cheese and coffee. It is believed to be involved in several physiological processes in the body, such as regulating gut motility and signaling. Skatole is being studied for its potential role in various health conditions, including cancer and neurological disorders. '

Cross-References

ID SourceID
PubMed CID6736
CHEMBL ID1329793
CHEBI ID9171
SCHEMBL ID5396
MeSH IDM0019919

Synonyms (77)

Synonym
AC-13010
3-methyl-4,5-benzopyrrole
CHEBI:9171 ,
beta-methylindole
scatole
skatol
wln: t56 bmj d1
1h-indole, 3-methyl-
nsc122024
.beta.-methylindole
nsc-122024
3-mi
indole, 3-methyl-
nsc 122024
einecs 201-471-7
fema no. 3019
hsdb 3511
ai3-24372
ccris 8961
3-methyl-1h-indole
inchi=1/c9h9n/c1-7-6-10-9-5-3-2-4-8(7)9/h2-6,10h,1h
C08313
3-methylindole
83-34-1
skatole ,
3-methylindole, 98%
skatole, >=98%
NCGC00167540-01
M-3898
MLS001332538
MLS001332537
smr000677925
3-methyl indole
3 methylindole
STK033388
AP-065/40182778
BMSE000516
M0347
AKOS005254880
dtxsid8021775 ,
tox21_112537
dtxcid601775
cas-83-34-1
HMS2233B05
9w945b5h7r ,
unii-9w945b5h7r
FT-0616165
AM1199
S4959
HMS3371O13
skatolum [hpus]
3-methyl-indole
skatolum
3-methylindole [hsdb]
skatole [fhfi]
skatole [mi]
CCG-214598
SCHEMBL5396
NCGC00167540-03
tox21_112537_1
CG-0502
CHEMBL1329793
3-methyl-1h-indol
mfcd00005627
CS-W007355
3-methylindole, analytical standard
b-methylindole
Q412281
HY-W007355
BCP00912
BRD-K73824630-001-03-2
SB14956
3-?methylindole
P10013
n-tert-butylbenzenesulfinimidoylchloride
EN300-41009
Z415653134

Research Excerpts

Overview

Skatole (3MI) is a major contributor to the malodor emission resulting from ruminant and human faeces. Skatole is a pulmonary toxin that induces the expression of aryl hydrocarbon receptor (AhR) regulated genes, such as cytochrome P450 1A1.

ExcerptReferenceRelevance
"Skatole is a malodorous compound that contributes to the characteristic smell of animal faeces. "( Indoleacetate decarboxylase is a glycyl radical enzyme catalysing the formation of malodorant skatole.
Ang, EL; Hu, Y; Jiang, L; Liu, D; Liu, X; Liu, Y; Nanjaraj Urs, AN; Wang, F; Wei, Y; Yin, J; Zhang, Y; Zhao, H; Zhao, S; Zhou, Y, 2018
)
2.14
"Skatole is a tryptophan metabolite produced by intestinal bacteria in gut and catabolised in liver."( Identification of the novel candidate genes and variants in boar liver tissues with divergent skatole levels using RNA deep sequencing.
Cinar, MU; Frieden, L; Große-Brinkhaus, C; Gunawan, A; Hölker, M; Looft, C; Neuhoff, C; Sahadevan, S; Schellander, K; Tesfaye, D; Tholen, E; Uddin, MJ; Wondim, DS, 2013
)
1.33
"Skatole (3MI) is a major contributor to the malodor emission resulting from ruminant and human faeces. "( Skatole remediation potential of Rhodopseudomonas palustris WKU-KDNS3 isolated from an animal waste lagoon.
Alok, PC; Choudhary, M; Doerner, KC; Sharma, N, 2015
)
3.3
"Skatole is a pulmonary toxin that induces the expression of aryl hydrocarbon receptor (AhR) regulated genes, such as cytochrome P450 1A1 (CYP1A1), in human bronchial cells."( Skatole (3-Methylindole) Is a Partial Aryl Hydrocarbon Receptor Agonist and Induces CYP1A1/2 and CYP1B1 Expression in Primary Human Hepatocytes.
Balaguer, P; Daujat-Chavanieu, M; Ekstrand, B; Gerbal-Chaloin, S; Rasmussen, MK, 2016
)
2.6

Effects

Skatole has an anti-lipid peroxidation effect and is a biomarker for several diseases. Skatole metabolites have been considered as putative contributors to boar taint.

ExcerptReferenceRelevance
"Skatole has an anti-lipid peroxidation effect and is a biomarker for several diseases."( Natural Product Skatole Ameliorates Lipotoxicity-Induced Multiple Hepatic Damage under Hyperlipidemic Conditions in Hepatocytes.
Hong, SH; Hong, Y; Keum, BR; Kim, GH; Lee, M, 2023
)
1.98
"Skatole has been used in specific products of the perfume industry or as a flavor additive in ice cream."( Skatole: A thin red line between its benefits and toxicity.
Vrzal, R; Zgarbová, E, 2023
)
3.07
"Skatole has an anti-lipid peroxidation effect and is a biomarker for several diseases."( Natural Product Skatole Ameliorates Lipotoxicity-Induced Multiple Hepatic Damage under Hyperlipidemic Conditions in Hepatocytes.
Hong, SH; Hong, Y; Keum, BR; Kim, GH; Lee, M, 2023
)
1.98
"Skatole has also been identified as a potential marker of interest for authenticating pasture-fed lamb meat."( Change in fat skatole and indole content in lambs switched from a concentrate-based diet indoors to alfalfa grazing for various durations before slaughter.
Prache, S; Prunier, A; Rey-Cadilhac, L, 2023
)
1.99
"Skatole metabolites have been considered as putative contributors to boar taint. "( 2-Aminoacetophenone Is the Main Volatile Phase I Skatole Metabolite in Pietrain × Baden-Württemberg Hybrid Type Boars.
Elsinghorst, PW; Gerlach, C; Schmarr, HG; Wüst, M, 2016
)
2.13

Toxicity

ExcerptReferenceRelevance
" Exposure of rat or mouse splenic cells to 3-MI (1 mM) in vitro resulted in toxic changes over 24 hr."( 3-Methylindole-induced splenotoxicity: biochemical mechanisms of cytotoxicity.
Kiorpes, AL; Marcus, CB; Pfeifer, RW; Robinson, JP; Updyke, LW; Yoon, HL, 1991
)
0.28
"In this laboratory, 3-methylindole (3-MI), a pneumotoxic metabolite of L-tryptophan that forms in the digestive tract of humans and ruminants, has been demonstrated to be toxic to rat and mouse splenic cells both in vitro and in vivo."( 3-Methylindole-induced splenotoxicity: functional analysis of immune parameters and lymphocyte phenotyping by flow cytometry.
Kiorpes, AL; Marcus, CB; Pfeifer, RW; Robinson, JP; Updyke, LW; Yoon, HL, 1991
)
0.28
" The production of a toxic metabolite in the livers of glutathione-depleted mice that is circulated to susceptible renal cells may be the mechanism of this interesting organ-selective shift in toxicity of 3MI."( Organ-selective switching of 3-methylindole toxicity by glutathione depletion.
Kuntz, DJ; McGill, LD; Yost, GS, 1990
)
0.28
" In agreement with this hypothesis, deutero-3-methylindole was synthesized and was shown to be significantly less toxic (LD50 735 mg/kg) than 3-methylindole (LD50 578 mg/kg)."( Decreased pneumotoxicity of deuterated 3-methylindole: bioactivation requires methyl C-H bond breakage.
Adams, JD; Huijzer, JC; Yost, GS, 1987
)
0.27
" Furthermore, the suggestion is made, that the alterations may signify the early changes of pulmonary hypertension induced by the toxic effect of 3MI in cattle."( Ultrastructural pathology of intrapulmonary arteries in 3-methylindole-induced pneumotoxicity in cattle: II. Glycogen accumulation in the smooth muscle cells and intimal changes.
Atwal, OS; Persofsky, MS, 1984
)
0.27
" 3MI is bioactivated to toxic intermediates by cytochrome P450 enzymes."( Production and characterization of specific antibodies: utilization to predict organ- and species-selective pneumotoxicity of 3-methylindole.
Kaster, JK; Yost, GS, 1997
)
0.3

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic plasma-concentration profiles for 3MI (10- and 20-mg/kg dosages) in horses were represented by a 2-compartment open model with first-order absorption, as determined by nonlinear least-squares regression analysis."( Pharmacokinetics of small doses of 3-methylindole given to horses.
Beadle, RE; Thomas, DE, 1985
)
0.27

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" It was concluded that differences in 3MI dosage response may exist between young calves and adult cattle in which calves are more resistant to the pulmonary cytotoxicity of 3MI."( Pathophysiologic studies of calves given 3-methylindole intraruminally.
Cornelius, LM; Coulter, D; Doster, A; Rawlings, C, 1979
)
0.26
" The protective effect of inhibitors when administered before, but not after, 3MI dosing suggests it is the inhibition of PHS activity in activation of 3MI, not in production of prostanoids which prevented the disease process."( The role of prostaglandin H synthase in 3-methylindole-induced pneumotoxicity in goat.
Acton, KS; Boermans, HJ; Bray, TM, 1992
)
0.28
" Plasma 3MI was still detectable 12 and 36 hours after dosing in phenobarbital-treated and control ponies, respectively."( Effects of phenobarbital treatment on 3-methylindole toxicosis in ponies.
Thomas, DE; Turk, MA, 1986
)
0.27
"In 5 Friesian calves given 3-methylindole (3-MI) (100 mg/kg once a week for 8 weeks, except calf 4, given a 50 mg/kg dose on weeks 3 to 8), pulmonary function (PF) values and arterial blood gas tensions (PaO2 and PaCO2) were measured 24 hours after dosing was done and were correlated with clinical, biochemical, and pathologic changes."( Pathophysiologic study of 3-methylindole-induced pulmonary toxicosis in immature cattle.
Breukink, HJ; Hajer, R; Lekeux, P; van den Ingh, TS, 1985
)
0.27
"Five to six month-old lambs of two different Norwegian breeds (Dala and Rygja) were dosed with 3-methyl indole (3MI) and DL-tryptophan (DL-T), and examined clinically, hematologically and post mortem."( 3-Methylindole-induced pulmonary injury in lambs. A comparison with acute respiratory distress syndrome (ARDS).
Ulvund, MJ,
)
0.13
" Steer 1 was dosed twice resulting in a total of 45 absorption measurements."( Net absorption of 3-methylindole and indole in cattle after oral administration of L-tryptophan.
Breeze, RG; Hammond, AC; Huntington, GB, 1983
)
0.27
" Clinical signs developed 48 to 72 h after dosing and were most severe between Days 4 and 10 post dosing."( 3-methylindole as a model of equine obstructive lung disease.
Breeze, RG; Brown, CM; Turk, MA, 1984
)
0.27
" The lung contained significantly more residual radioactivity 4 h after dosing compared with other tissues and the elevated radioactivity persisted for 3 days."( Tissue and subcellular distribution and excretion of 3-[14C]methylindole in rabbits after intratracheal infusion.
Bray, TM; Carlson, JR, 1980
)
0.26
" In a follow-up study, additional odorant-trained rats were dosed with 0, 100, 200, or 300 mg/kg of 3-MI ip and olfactory function reassessed 6 days later."( Design and evaluation of an olfactometer for the assessment of 3-methylindole-induced hyposmia.
Bowman, JR; Dorman, DC; James, RA; Morgan, KT; Moss, OR; Owens, JG; Struve, MF, 1996
)
0.29
" Blood, urine and ruminal fluid were collected immediately prior to 3MI dosing (0."( Effect of melengestrol acetate on development of 3-methylindole-induced pulmonary edema and emphysema in sheep.
Ayroud, M; Cheng, KJ; Karren, D; Kastelic, JP; Majak, W; McAllister, TA; Popp, JD; VanderKop, MA; Yost, GS, 1998
)
0.3
" The light microscopic appearance and collagen staining of the lungs of the dually treated rats were similar to the negative control rat lungs 2 weeks after dosing with 3-MI."( Manipulation of injury and repair of the alveolar epithelium using two pneumotoxicants: 3-methylindole and monocrotaline.
Segall, HJ; Wilson, DW; Woods, LW, 1999
)
0.3
" To evaluate the effect of 3MI on equine olfactory mucosa, ponies were dosed orally with 100 mg 3MI/kg (n = 9) or corn oil vehicle (n = 6)."( 3-methylindole induces transient olfactory mucosal injury in ponies.
Evans, TJ; Ganjam, VK; Johnson, PJ; Kottler, SJ; Miller, MA; Ramos-Vara, JA, 2003
)
0.32
" after dosage show that this substance does not accumulate in the body."( THE FATE OF 2,4,6-TRI-(3',5'-DI-TERT.-BUTYL-4'-HYDROXYBENZYL)MESITYLENE (IONOX 330) IN THE DOG AND RAT.
CROWNE, RS; HATHWAY, DE; WRIGHT, AS, 1965
)
0.24
"In responding to Drs Calabrese and Baldwin's question, 'At what point, if ever, should hormesis be employed as the principal dose response default assumption in risk assessment?', we examined the benefits of replacing traditional dose-response with hormesis."( Examining the risks and benefits of replacing traditional dose-response with hormesis.
Oehme, FW; Pickrell, JA, 2005
)
0.33
" As a result of an antibacterial assay using a paper disk, actinokineosin showed antibacterial activity against Micrococcus luteus at a dosage of 50 μg per disk."( Isolation of a new antibacterial peptide actinokineosin from Actinokineospora spheciospongiae based on genome mining.
Kaweewan, I; Kodani, S; Ohnishi-Kameyama, M; Takasaka, N, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
mammalian metaboliteAny animal metabolite produced during a metabolic reaction in mammals.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
methylindoleAny member of the class of indoles carrying one or more methyl substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
Metabolism14961108
Biological oxidations150276
Phase I - Functionalization of compounds69175
Cytochrome P450 - arranged by substrate type30110
Xenobiotics450
Tryptophan metabolism2342

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency6.30960.044717.8581100.0000AID485294
GLI family zinc finger 3Homo sapiens (human)Potency14.96010.000714.592883.7951AID1259369; AID1259392
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency29.01450.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency1.17820.001530.607315,848.9004AID1224841; AID1259401
serine-protein kinase ATM isoform aHomo sapiens (human)Potency35.48130.707925.111941.2351AID485349
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency44.66843.548119.542744.6684AID743266
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency2.81840.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency2.81840.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency2.81840.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency2.81840.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (47)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1133965Antiulcer activity in sc dosed albino rat pyloric ligation model assessed as inhibition of gastric secretion administered as single dose 1 to 24 hrs prior to ligation1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Experimental antiulcer drugs. 1. Indole-1-alkanamides and pyrrole-1-alkanamides.
AID1133966Antiulcer activity in po dosed albino rat pyloric ligation model assessed as inhibition of gastric secretion administered as single dose 1 to 24 hrs prior to ligation1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Experimental antiulcer drugs. 1. Indole-1-alkanamides and pyrrole-1-alkanamides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (616)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990192 (31.17)18.7374
1990's90 (14.61)18.2507
2000's97 (15.75)29.6817
2010's195 (31.66)24.3611
2020's42 (6.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.09 (24.57)
Research Supply Index6.49 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index95.01 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (56.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (2.18%)5.53%
Reviews23 (3.59%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (0.16%)0.25%
Other603 (94.07%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]